Glycine, N-[(3-methoxy-2-pyridinyl)carbonyl]- | 170622-36-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Glycine, N-[(3-methoxy-2-pyridinyl)carbonyl]-
• 英文别名: 2-[(3-methoxypyridine-2-carbonyl)amino]acetic acid
• CAS: 170622-36-3
• 化学式: C₉H₁₀N₂O₄
• 分子量: 210.19
• InChiKey: VMSRIULANPDJAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  88.5
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Stabilization of hypoxia inducible factor (HIF) alpha
  申请人：FIBROGEN, INC.

  公开号：EP2295059A2

  公开（公告）日：2011-03-16

  The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.

  本发明涉及稳定缺氧诱导因子（HIF）α亚基的方法。本发明进一步涉及预防、预处理或治疗与 HIF 相关的病症（包括缺血和缺氧病症）的方法。本发明还提供了用于这些方法的化合物。
• Medicaments for increasing endogenous erythropoietine (EPO)
  申请人：FIBROGEN, INC.

  公开号：EP2289531A2

  公开（公告）日：2011-03-02

  The present invention relates to compounds for use in methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Compounds for use in methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included.

  本发明涉及用于通过在体外和体内增加内源性促红细胞生成素来治疗促红细胞生成素相关疾病的方法的化合物。本发明还包括用于治疗、预处理或预调节或预防促红细胞生成素相关疾病的化合物。
• Medicaments for increasing endogenous Erythropoietin (EPO)
  申请人：Fibrogen, Inc.

  公开号：EP2298301A2

  公开（公告）日：2011-03-23

  The present invention relates to compounds for use in methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Compounds for use in methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included.

  本发明涉及用于通过在体外和体内增加内源性促红细胞生成素来治疗促红细胞生成素相关疾病的方法的化合物。本发明还包括用于治疗、预处理或预调节或预防促红细胞生成素相关疾病的化合物。
• Use of HIF Alpha stabilizers for enhancing erythropoiesis
  申请人：Fibrogen, Inc.

  公开号：EP2322153A1

  公开（公告）日：2011-05-18

  The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.

  本发明涉及调节或增强红细胞生成和铁代谢以及治疗或预防慢性病缺铁和贫血的方法和化合物。
• Treatment of hypertension
  申请人：Fibrogen, Inc.

  公开号：EP2327399A1

  公开（公告）日：2011-06-01

  The present invention relates to compounds that stabilizes HIFα for use in a) treating or preventing hypertension; or b) decreasing blood triglyceride levels in a mammalian subject.

  本发明涉及稳定 HIFα 的化合物，可用于 a) 治疗或预防高血压；或 b) 降低哺乳动物体内的血液甘油三酯水平。